IVD China last week: Danaher, Siemens Healthineers and Novartis, YHLO and Sanofi, Berry Genomics and Illumina, Sinopharm and BD

Danaher and Shanghai Shangsi Institute of Natural Sciences signed a strategic cooperation memorandum

On November 5, Danaher and Shanghai Shangsi Institute of Natural Sciences signed a strategic cooperation memorandum. The two parties will focus on cutting-edge fields such as cell and gene therapy, biologics, and small molecule drugs, leveraging their respective global resources and innovative strengths. Collaboration will be carried out in areas including talent cultivation, technological innovation, achievement transformation, DBS management, resource sharing, and international cooperation to jointly promote the construction of an innovation ecosystem in the life and health industry. Through the innovative model of "technological breakthroughs, capital empowerment, and global layout," the partnership aims to empower basic scientific research and accelerate the translation of innovative achievements into clinical and industrial applications.

Siemens Healthineers and Novartis Sign Strategic Cooperation Memorandum

At the 8th China International Import Expo, Siemens Healthineers and Novartis signed a strategic cooperation agreement to fully leverage their respective expertise and technological strengths. The collaboration aims to advance the innovation, development, and widespread application of radioligand therapy (RLT) and molecular imaging systems in the field of integrated precision diagnosis and treatment for major diseases such as prostate cancer.

YHLO and Sanofi Join Hands to Build a Type 1 Diabetes Diagnosis and Treatment Ecosystem in China

On November 6, at the 8th China International Import Expo, the "China Type 1 Diabetes Ecosystem Co-construction Alliance" was officially launched. As a key innovator in China's in vitro diagnostics (IVD) industry, YHLO has partnered with Sanofi, a globally leading healthcare company, to become one of the collaborators in the alliance. Ecosystem partners will work together to strengthen clinical research, pilot early screening models, promote comprehensive disease management, and empower digital and intelligent integration. These efforts aim to advance the prevention and treatment of type 1 diabetes in China and jointly build a new diagnosis and treatment ecosystem.

Berry Genomics and Illumina Deepen Strategic Collaboration

On November 5, the 8th China International Import Expo (CIIE) grandly opened in Shanghai. During the event, Berry Genomics deepened its strategic collaboration with Illumina, a global leader in gene sequencing, to advance the clinical application of sequencing platforms and jointly promote clinical research innovation and the translation of achievements. Gao Yang, Chairman and General Manager of Berry Genomics, attended the signing ceremony.

Sinopharm Medical Equipment and BD Biosciences have established a strategic partnership

Recently, Sinopharm Medical Equipment and BD Biosciences (BDB) held a strategic cooperation signing ceremony at the headquarters of Sinopharm Medical Equipment. The milestone moment was jointly witnessed by Li Yang, Secretary of the Party Committee and Chairman of Sinopharm Medical Equipment; Chen Anbo, Deputy Secretary of the Party Committee and General Manager of Sinopharm Medical Equipment; and Wang Tong, Vice President of Biosciences for BD Greater China. Dang Tiefei, Vice President of Sinopharm Medical Equipment, and Zhao Yujin, National Sales and Marketing Director of Biosciences for BD Greater China, signed the strategic cooperation agreement on behalf of their respective parties. The two sides will join hands to open a new chapter of in-depth collaboration and mutual market expansion.